Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination Therapy with an Antitumor Alkaloid

a technology of antitumor alkaloid and combination therapy, which is applied in the direction of biocide, drug composition, metabolic disorder, etc., can solve the problems of limited efficacy of available treatments for many cancer types, ineffective or intolerable, and invasive cancer, and achieve the effect of potentiating antitumor activity

Inactive Publication Date: 2013-10-10
PHARMA MAR U
View PDF3 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about a new substance called PM01183 that can enhance the effectiveness of other anticancer drugs. This substance can be combined with other drugs like platinum coordination complexes, antimetabolites, mitotic inhibitors, and many others. The combination of PM01183 with other drugs can lead to better results in treating cancer. The patent text describes the use of PM01183 in combination therapy with other anticancer drugs and the manufacture of a pharmaceutical composition for this purpose. The invention is also about the use of PM0 1183 in synergistic combinations with other drugs. Overall, the patent text provides an effective tool to treat cancer by combining PM01183 with other drugs.

Problems solved by technology

In addition, cancer is invasive and tends to infiltrate the surrounding tissues and give rise to metastases.
However, the efficacy of available treatments for many cancer types is limited, and new, improved forms of treatment showing clinical benefits are needed.
This is especially true for those patients presenting with advanced and / or metastatic disease and for patients relapsing with progressive disease after having been previously treated with established therapies which become ineffective or intolerable due to acquisition of resistance or to limitations in administration of the therapies due to associated toxicities.
Unfortunately, more than 50% of all cancer patients either do not respond to initial therapy or experience relapse after an initial response to treatment and ultimately die from progressive metastatic disease.
Unfortunately, none of the current chemotherapies with these agents posses an ideal profile.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination Therapy with an Antitumor Alkaloid
  • Combination Therapy with an Antitumor Alkaloid
  • Combination Therapy with an Antitumor Alkaloid

Examples

Experimental program
Comparison scheme
Effect test

example 1

In Vitro Studies to Determine the Effect of PM01183 in Combination with Chemotherapeutic Agents on Human Lung Carcinoma Cell Lines

[0131]The objective of this study was to determine the ability of PM01183 to potentiate the antitumor activity of chemotherapeutic agents used in the treatment of lung carcinoma.

[0132]The following agents were evaluated in combination with PM01183: oxaliplatin, carmustine, cyclophosphamide, mytomicin C (stock solutions of these compounds prepared in sterile double distilled water and stored at −20° C.), 5-fluorouracil (5-FU), gemcitabine, paclitaxel, docetaxel, vincristine, daunorubicin, actinomycin D, topotecan, etoposide, bortezomib, vorinostat, dacarbazine, temsirolimus, erlotinib, ET-743 and PM00104 (stock solutions of these compounds prepared in pure DMSO and stored at −20° C.). Additional serial dilutions were prepared in serum-free culture medium to achieve a final 4× concentration. Aliquots of 50 μL of each diluted compound were added per well.

A54...

example 2

In Vitro Studies to Determine the Effect of PM01183 in Combination with Chemotherapeutic Agents on Human Sarcoma Cell Lines

[0137]The objective of this study was to determine the ability of PM01183 to potentiate the antitumor activity of chemotherapeutic agents used in the treatment of sarcoma.

[0138]The following agents were evaluated in combination with PM01183: cisplatin, oxaliplatin, cyclophosphamide, mytomicin C (stock solutions of these compounds prepared in sterile double distilled water and stored at −20° C.), gemcitabine, docetaxel, vincristine, vinorelbine, daunorubicin, cytarabine, actinomycin D, topotecan, etoposide, vorinostat, dacarbazine, temsirolimus, erlotinib, aplidine, PM02734, ET-743 and PM00104 (stock solutions of these compounds prepared in pure DMSO and stored at −20° C.). Additional serial dilutions were prepared in serum-free culture medium to achieve a final 4× concentration. Aliquots of 50 μL of each diluted compound were added per well.

A673 was the human rh...

example 3

In Vitro Studies to Determine the Effect of PM01183 in Combination with Chemotherapeutic Agents on Human Malignant Melanoma Cell Lines

[0142]The objective of this study was to determine the ability of PM01183 to potentiate the antitumor activity of chemotherapeutic agents used in the treatment of malignant melanoma.

[0143]The following agents were evaluated in combination with PM01183: cisplatin, mytomicin C (stock solutions of these compounds prepared in sterile double distilled water and stored at −20° C.), 5-fluorouracil, doxorubicin, daunorubicin, cytarabine, topotecan, irinotecan, methotrexate, etoposide, dacarbazine, temsirolimus, PM02734, ET-743 and PM00104 (stock solutions of these compounds prepared in pure DMSO and stored at −20° C.). Additional serial dilutions were prepared in serum-free culture medium to achieve a final 4× concentration. Aliquots of 50 μL of each diluted compound were added per well.

SK-MEL-2 was the human melanoma cell line selected for this assay. SK-MEL...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
humidityaaaaaaaaaa
humidityaaaaaaaaaa
humidityaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and / or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.

Description

FIELD OF THE INVENTION[0001]The present invention relates to the combination of PM01183 with other anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and / or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734, and PM00104 and the use of these combinations in the treatment of cancer.BACKGROUND OF THE INVENTION[0002]Cancer develops when cells in a part of the body begin to grow out of control. Although there are many kinds of cancer, they all arise from out-of-control growth of abnormal cells. Cancer cells can invade nearby tissues and can spread through the bloodstream and lymphatic system ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/4995A61K31/55A61K31/704A61K31/4164A61K31/513A61K31/7068A61K31/4188A61K31/4375A61K31/337A61K33/24A61K33/243
CPCA61K31/4995A61K31/337A61K31/519A61K31/69A61K31/7068A61K45/06A61K31/513A61K31/4164A61K31/4188A61K31/4375A61K31/704A61K31/55A61K38/15A61K33/24A61K2300/00A61K33/243A61P1/04A61P1/16A61P1/18A61P11/00A61P13/08A61P13/10A61P13/12A61P15/00A61P17/00A61P21/00A61P25/00A61P3/00A61P35/00A61P35/02A61P43/00Y02A50/30A61K31/34A61K31/395
Inventor MONEO OCANA, VICTORIAN NEZ, GEMA SANTAMARIAGARCIA FERNANDEZ, LUIS FRANCISCOGALMARINI, CARLOS MARIAGUILLEN NAVARRO, MARIA JOSEAVILES MARIN, PABLO MANUEL
Owner PHARMA MAR U
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com